MDM Templates

Low-Risk Chest Pain in HIV

Patient with HIV (on HAART, CD4 ***, viral load ***) presents with chest pain. They are well appearing, hemodynamically stable, and without hypoxia. No orthopnea, no volume overload, no pleuritic features. Oral exam without evidence of esophageal candidiasis. No night sweats, weight loss, or TB exposure history.

Given the known elevated cardiovascular risk associated with HIV and antiretroviral therapy, ACS was specifically considered. ECG is without ST changes or ischemic findings. History and exam also lower suspicion for PE, pneumothorax, pneumonia, aortic dissection, pericarditis, esophagitis, and tuberculosis.

Plan: Observation with serial assessment.
Disposition: Discharge with return precautions for recurrent chest pain, dyspnea, syncope, or fever. Follow up with PCP and ID within 48 hours.

---

Chest Pain with Concern for ACS or Opportunistic Process

Patient with HIV (CD4 ***, viral load ***, HAART compliance ***) presents with chest pain with features concerning for cardiac ischemia or pulmonary pathology. Given the elevated cardiovascular risk in HIV patients on HAART and the broad pulmonary differential in immunocompromised patients, a thorough workup is warranted.

History and exam raise concern for ACS, opportunistic pneumonia, TB, PE, or pericardial disease. Presentation warrants laboratory and imaging evaluation beyond what would be standard for an immunocompetent patient with this chief complaint.

Plan: ECG, troponin, CBC, BMP, LFTs, CXR. Lactate and blood cultures if febrile. CT chest if concern for PE, TB, or PCP.

If workup reassuring:
Disposition: Discharge with close PCP and ID follow-up within 24-48 hours. Return precautions for worsening pain, dyspnea, or fever.

If ACS, PCP pneumonia, or TB suspected:
Disposition: Admit for further workup and treatment. ID consultation.

---

Clinical Education

HIV and Cardiovascular Risk

HIV patients have 1.5-2x the risk of MI compared to the general population. This is driven by chronic inflammation from HIV itself, metabolic effects of antiretroviral therapy (particularly older PIs which cause dyslipidemia and insulin resistance), and higher rates of traditional risk factors (smoking, substance use).^[1]

Protease inhibitors (especially older agents like lopinavir/ritonavir) are most strongly associated with cardiovascular risk. Abacavir has also been linked to increased MI risk in some studies, though data is conflicting. Newer integrase inhibitors (dolutegravir, bictegravir) have a more favorable metabolic profile.^[1]

Clinical implication: Maintain a lower threshold for ACS workup in HIV patients with chest pain, even in younger patients without traditional risk factors. An HIV patient on HAART with chest pain deserves an ECG and troponin.

---

Pulmonary Differential in HIV

The pulmonary differential in HIV expands dramatically when CD4 drops below 200. Above 200, think community-acquired pneumonia, TB, and typical causes. Below 200, add PCP (Pneumocystis jirovecii), CMV pneumonitis, Kaposi sarcoma, and fungal infections.^[2]

CD4 Count	Key Pulmonary Considerations
>500	Same as immunocompetent: CAP, PE, COPD/asthma, TB (if risk factors)
200-500	Above + TB (reactivation), bacterial pneumonia (recurrent), lymphoma
<200	Above + PCP, disseminated fungal (histo, crypto, cocci), CMV, Kaposi sarcoma, MAC

Proxy for CD4: If CD4 count is unknown, the absolute lymphocyte count (ALC) from a CBC can approximate it. ALC <1000 is predictive of CD4 2000 is predictive of CD4 >200.^[2]

---

CD4 Count Framework

Knowing the CD4 count changes your differential more than any other single data point in HIV. Patients with CD4 >500 on suppressive HAART are functionally immunocompetent and should be worked up like any other patient. The HIV-specific differential only broadens when CD4 drops, adherence lapses, or the patient is newly diagnosed and untreated.^[3]

PCP prophylaxis status matters: A patient with CD4 <200 who is on Bactrim prophylaxis has a much lower risk of PCP than one who is not. Always ask about prophylactic medications.

Pericardial disease in HIV: Pericardial effusion occurs in up to 20% of AIDS patients. Causes include TB (most common worldwide), Kaposi sarcoma, lymphoma, and idiopathic. Cardiac tamponade warrants emergent pericardiocentesis regardless of etiology.^[3]

---

References

1. Freiberg MS et al. HIV Infection and the Risk of Acute Myocardial Infarction. JAMA Intern Med. 2013;173(8):614-622. PubMed
2. Huang L et al. HIV-Associated Opportunistic Pneumonias. Proc Am Thorac Soc. 2011;8(3):294-300. PubMed
3. Barbaro G. Cardiovascular Manifestations of HIV Infection. Circulation. 2002;106(11):1420-1425. PubMed